Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Amitriptyline Concomitant use of boosted Clinical monitoring is recommended
Desipramine darunavir and these antidepressants when co-administering boosted
Imipramine may increase concentrations of the darunavir with these antidepressants
Nortriptyline antidepressant. and a dose adjustment of the
Trazodone (CYP2D6 and/or CYP3A antidepressant may be needed.
inhibition)
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and dose
considerations darunavir co- adjustment of metformin is
administered with cobicistat is recommended in patients who are
expected to increase metformin taking darunavir co-administered
plasma concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for darunavir co-
administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may Voriconazole should not be
decrease plasma concentrations of combined with boosted darunavir
voriconazole. unless an assessment of the
(induction of CYP450 enzymes) benefit/risk ratio justifies the use of
voriconazole.
Concentrations of voriconazole may
increase or decrease when co-
administered with darunavir co-
administered with cobicistat.
(inhibition of CYP450 enzymes)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Based on theoretical considerations
Amitriptyline DRV/COBI is expected to increase
Desipramine these anti-depressant plasma
Imipramine concentrations.
Nortriptyline (CYP2D6 and/or CYP3A
Trazodone inhibition)
ANTI-DIABETICS
Metformin Based on theoretical considerations Careful clinical monitoring and
DRV/COBI is expected to increase dose adjustment of metformin is
metformin plasma concentrations. recommended in patients who are
(MATE1 inhibition) taking Symtuza.
ANTIEMETICS
Domperidone Not studied. Co-administration of
domperidone with Symtuza is
contraindicated.
ANTIFUNGALS
Clotrimazole Based on theoretical considerations Caution is warranted and clinical
Fluconazole DRV/COBI is expected to increase monitoring is recommended.
Itraconazole these antifungal plasma When co-administration is
concentrations, and darunavir, required, the daily dose of
Isavuconazole cobicistat and/or tenofovir itraconazole should not exceed
Posaconazole alafenamide plasma concentrations 200 mg.
may be increased by the
antifungals.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Co-administration of vorasidenib with CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4 substrates
with narrow therapeutic index (including, but not limited to, amitriptyline, alfentanil, carbamazepine,
ciclosporin, dosulepin, everolimus, fentanyl, fosphenytoin, ifosfamide, imipramine, phenobarbital,
phenytoin, pimozide, quinidine, sirolimus, tacrolimus, tamoxifen, trimipramine, valproic acid, and
warfarin) may decrease the plasma concentrations of these medicinal products. Concomitant use of
substrates of these enzymes with narrow therapeutic index should be avoided in patients taking
vorasidenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-08-27T16:33:00Z · SHA-256 2232f34043666605447d216a0f9efae95496605e48741a446bf6879643808d62 · Passage 3d550b9ad3b19c779ebfbf7d68a0ec9fc3073bab44b0453f3efc8e4f9e0983a9 · Zeichen 1607–2205 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.